ospemifene for dyspareunia
Selected indexed studies
- Ospemifene for the treatment of dyspareunia in postmenopausal women. (Drugs Today (Barc), 2014) [PMID:24918836]
- Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women. (Pharmacotherapy, 2014) [PMID:25052122]
- Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. (Int J Womens Health, 2013) [PMID:24109197]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Hormone Therapy and Other Treatments for Symptoms of Menopause. (2016) pubmed
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. (2024) pubmed
- Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. (2023) pubmed
- Ospemifene for the treatment of dyspareunia in postmenopausal women. (2014) pubmed
- Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women. (2014) pubmed
- Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. (2013) pubmed
- PMID:38748822 (2022) pubmed
- Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. (2014) pubmed
- Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. (2016) pubmed
- Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. (2014) pubmed